Minerva Surgical Reports Second Quarter 2022 Financial Results
Minerva Surgical reported second-quarter 2022 revenue of $13.0 million, up from $10.9 million in Q1 2022 but down from $14.1 million in Q2 2021. Symphion revenue rose by 19% from Q1 2022, while endometrial ablation products fell by 14% compared to Q2 2021. Gross margin improved to 59%, though lower than 61.9% in the previous year. Operating expenses decreased to $12.5 million, and net loss narrowed to $5.6 million. Annual revenue guidance is reduced to $50-$53 million due to COVID-19 impacts on elective surgeries.
- Revenue increased 19% from Q1 2022.
- Gross margin improved to 59.0% from 49.5% in Q1 2022.
- Operating expenses decreased significantly to $12.5 million.
- Revenue decreased 8% compared to Q2 2021.
- Endometrial ablation revenue down 14% compared to Q2 2021.
- Annual revenue guidance reduced to $50-$53 million.
SANTA CLARA, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), today reported second quarter financial results for the period ended June 30, 2022.
Second Quarter and Recent Business Highlights:
- Reported revenue of
$13.0 million in the second quarter of 2022, compared with revenue of$10.9 million in the first quarter of 2022 and$14.1 million in the second quarter of 2021 - Symphion revenue of
$3.3 million increased19% from the first quarter of 2022, and20% from the second quarter of 2021 - Minerva endometrial ablation revenue of
$5.8 million was up20% from the first quarter of 2022, and down14% from the second quarter of 2021 - DTC (direct-to-consumer) digital marketing campaign launched in 10 markets
- Website visitors for AUBandMe.com, an educational website which was launched in the fourth quarter of 2021, were up from less than 2,000 visitors in the first quarter of 2022 to over 40,000 new visitors in the most recent quarter
47% of Minerva Surgical’s business is now under contract, up from37% in 2021
Second Quarter 2022 Financial Results
Revenue was
Overall gross margin was
Operating expenses were
Net loss in the second quarter of 2022 was
Adjusted EBITDA for the second quarter of 2022 was negative
Financial Outlook for Fiscal Year 2022
Due to the ongoing impacts of COVID-19 on elective ablation procedures, our annual revenue guidance for 2022 is being reduced to a range of
Webcast and Conference Call Information
Minerva Surgical will host a conference call to discuss the second quarter 2022 financial results after market close on Tuesday, August 9, 2022 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that can be used to join the call. The live webinar can be accessed at https://ir.minervasurgical.com.
Use of Non-GAAP Financial Measures
Adjusted EBITDA and Adjusted EBITDA Margin
To provide investors with additional information regarding the Company’s financial results, it has provided EBITDA and adjusted EBITDA. The Company calculates EBITDA, a non-GAAP financial measure, as net income/(loss) excluding depreciation and amortization, interest income and expense and income tax benefit. The Company calculates adjusted EBITDA, a non-GAAP financial measure by further excluding non-cash items for stock-based compensation expenses, gain on extinguishment of PPP loan, change in fair value of redeemable convertible preferred stock warrant liability, change in fair value of contingent consideration liability and change in fair value of derivative liabilities. EBITDA margin represents EBITDA as a percentage of revenue. Adjusted EBITDA margin represents Adjusted EBITDA as a percentage of revenue. EBITDA and Adjusted EBITDA should be viewed as measures of operating performance that are supplements to, and not substitutes for, operating (income) loss, net (income) loss and other U.S. GAAP measures of income and loss.
The Company has included adjusted EBITDA in this earnings release because it is a key measure used by the Company’s management and board of directors to evaluate and compare the Company’s financial and operational performance over multiple periods, identifying trends affecting the Company’s business, formulating business plans and making strategic decisions. In particular, the exclusion of certain expenses in calculating adjusted EBITDA facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and certain non-recurring variable charges. In addition, the Company believes that providing each of EBITDA and Adjusted EBITDA, together with a reconciliation of net loss to each such measure, helps investors make comparisons between Minerva Surgical and other companies that may have different capital structures, different tax rates, and/or different forms of employee compensation.
Each of EBITDA and Adjusted EBITDA is used by the Company’s management team as an additional measure of Company performance for purposes of business decision-making, including managing expenditures, and evaluating potential acquisitions. Period-to-period comparisons of EBITDA and Adjusted EBITDA help the Company’s management identify additional trends in our financial results that may not be shown solely by period-to-period comparisons of net income or income from continuing operations. Each of EBITDA and Adjusted EBITDA has inherent limitations because of the excluded items, and may not be directly comparable to similarly titled metrics used by other companies.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements may include information regarding trends and expectations for the Company’s products and technology, demand for the Company’s products, the Company’s expected financial performance, expenses, and position in the market and outlook for fiscal year 2022, and the impact of COVID-19 and its variants on the Company’s operations and those of its customers. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2022, as filed with the U.S. Securities and Exchange Commission (SEC) on August 9, 2022, and available at www.SEC.gov. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical fact are forward-looking statements. Except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the Company’s business.
About Minerva Surgical, Inc.
Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. The Company has established a broad product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of Abnormal Uterine Bleeding (AUB) in most uterine anatomies. The Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies.
Contact:
Media/Press: Mike Clapper– mike.clapper@minervasurgical.com
Investors: Caroline Corner- caroline.corner@westwicke.com
www.minervasurgical.com
www.AUBandMe.com
Minerva Surgical, Inc.
Condensed Statements of Operations
(in thousands, except share and per share amounts)
(unaudited)
Three Months Ended June 30 | Six Months Ended June 30 | ||||||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||||||
Revenues | $ | 12,967 | $ | 14,114 | $ | 23,902 | $ | 25,952 | |||||||
Cost of goods sold | 5,322 | 5,382 | 10,844 | 10,387 | |||||||||||
Gross profit | 7,645 | 8,732 | 13,058 | 15,565 | |||||||||||
Operating expenses | |||||||||||||||
Sales and marketing | 9,691 | 8,497 | 19,164 | 14,964 | |||||||||||
General and administrative | 1,579 | 10,125 | 6,564 | 14,128 | |||||||||||
Research and development | 1,274 | 1,673 | 2,529 | 2,824 | |||||||||||
Total operating expenses | 12,544 | 20,295 | 28,257 | 31,916 | |||||||||||
Loss from operations | (4,899 | ) | (11,563 | ) | (15,199 | ) | (16,351 | ) | |||||||
Interest income | 19 | — | 28 | — | |||||||||||
Interest expense (includes $nil million and | (703 | ) | (3,601 | ) | (1,335 | ) | (7,052 | ) | |||||||
Change in fair value of derivative liabilities | — | (2,019 | ) | — | (8,140 | ) | |||||||||
Gain on extinguishment of PPP loan | — | 3,036 | — | 3,036 | |||||||||||
Other income (expense), net | (30 | ) | 48 | (32 | ) | (540 | ) | ||||||||
Net loss before income taxes | (5,613 | ) | (14,099 | ) | (16,538 | ) | (29,047 | ) | |||||||
Income tax benefit (expense) | — | — | — | — | |||||||||||
Net loss | $ | (5,613 | ) | $ | (14,099 | ) | $ | (16,538 | ) | $ | (29,047 | ) | |||
Net loss per share attributable to common stockholders, basic and diluted | $ | (0.20 | ) | $ | (5.48 | ) | $ | (0.58 | ) | $ | (15.49 | ) | |||
Weighted-average common shares used in computing net loss per share, basic and diluted | 28,550,489 | 2,573,705 | 28,515,808 | 1,875,691 | |||||||||||
Minerva Surgical, Inc.
Condensed Balance Sheets
(in thousands, except share and per share amounts)
(Unaudited)
June 30, 2022 | December 31, 2021 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 22,386 | $ | 40,608 | ||||
Restricted cash, current | 7,807 | 7,283 | ||||||
Accounts receivable, net | 7,017 | 7,292 | ||||||
Inventory | 16,928 | 15,682 | ||||||
Prepaid expenses and other current assets | 3,139 | 4,139 | ||||||
Total current assets | 57,277 | 75,004 | ||||||
Restricted cash, net of current portion | — | 524 | ||||||
Intangible assets, net | 30,916 | 34,970 | ||||||
Property and equipment, net | 5,179 | 4,594 | ||||||
Operating lease right-of-use asset | 586 | — | ||||||
Total assets | $ | 93,958 | $ | 115,092 | ||||
Liabilities and stockholders’ equity | ||||||||
Current Liabilities: | ||||||||
Accounts payable | $ | 3,273 | $ | 3,629 | ||||
Accrued compensation | 3,467 | 3,518 | ||||||
Accrued liabilities | 11,386 | 10,662 | ||||||
Contingent consideration liability, current | 5,000 | 5,000 | ||||||
Operating lease liability | 774 | — | ||||||
Total current liabilities | 23,900 | 22,809 | ||||||
Long-term debt | 39,208 | 39,085 | ||||||
Contingent consideration liability, net of current portion | — | 9,094 | ||||||
Total liabilities | 63,108 | 70,988 | ||||||
Commitments and contingencies (Note 8) | ||||||||
Stockholders` equity: | ||||||||
Preferred stock, | — | — | ||||||
Common stock, | 28 | 28 | ||||||
Additional paid-in capital | 296,905 | 293,621 | ||||||
Accumulated other comprehensive income | 11 | 11 | ||||||
Accumulated deficit | (266,094 | ) | (249,556 | ) | ||||
Total stockholders’ equity | 30,850 | 44,104 | ||||||
Total liabilities and stockholders’ equity | $ | 93,958 | $ | 115,092 | ||||
Non-GAAP Financial Measures
Adjusted EBITDA and Adjusted EBITDA Margin: The following table presents reconciliation of net loss to adjusted EBITDA for each of the periods indicated.
Three Months Ended June 30 | Six Months Ended June 30 | ||||||||||||||
(in thousands, except percentage figures) | 2022 | 2021 | 2022 | 2021 | |||||||||||
Net Loss | $ | (5,613 | ) | $ | (14,099 | ) | $ | (16,538 | ) | $ | (29,047 | ) | |||
Depreciation and amortization | 2,693 | 2,691 | 5,361 | 5,334 | |||||||||||
Interest (income) expense, net | 684 | 3,601 | 1,307 | 7,052 | |||||||||||
EBITDA | (2,236 | ) | (7,807 | ) | (9,870 | ) | (16,661 | ) | |||||||
EBITDA margin | (17.2 | %) | (55.3 | %) | (41.3 | %) | (64.2 | %) | |||||||
Adjustments: | |||||||||||||||
Gain on extinguishment of PPP loan | — | (3,036 | ) | — | (3,036 | ) | |||||||||
Stock-based compensation expense | 1,676 | 4,478 | 3,199 | 4,609 | |||||||||||
Change in fair value of redeemable convertible preferred stock warrant liability | — | (50 | ) | — | 532 | ||||||||||
Change in fair value of contingent consideration liability | (3,943 | ) | 1,121 | (4,094 | ) | 917 | |||||||||
Change in fair value of derivative liabilities | — | 2,019 | — | 8,140 | |||||||||||
Adjusted EBITDA | $ | (4,503 | ) | $ | (3,275 | ) | $ | (10,765 | ) | $ | (5,499 | ) | |||
Adjusted EBITDA margin | (34.7 | %) | (23.2 | %) | (45.0 | %) | (21.2 | %) | |||||||
FAQ
What were Minerva Surgical's second quarter 2022 revenues?
How did Symphion revenue perform in the second quarter of 2022?
What is Minerva Surgical's adjusted EBITDA for Q2 2022?